☆ 4.4 Article

When should Surgery be used for Recurrent Ovarian Carcinoma?

CLINICAL ONCOLOGY (2018)

Journal

CLINICAL ONCOLOGY

Volume 30, Issue 8, Pages 493-497

Publisher

ELSEVIER SCIENCE LONDON

DOI: 10.1016/j.clon.2018.04.006

Keywords

Ovarian cancer; recurrence; secondary cytoreductive surgery

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Cytoreductive surgery is an important column in the treatment of primary ovarian cancer. Surgical outcome is one of the most important prognostic factors and one of the few prognostic variables that can be influenced by therapists. Retrospective studies suggested that only complete cytoreduction was associated with a benefit. Therefore, definition of predictors of complete resection is of the utmost importance to avoid surgical burden in patients with both limited benefit of the procedure and limited overall life expectancy. Two prospective multicentre randomised surgical trials in platinum-sensitive recurrent ovarian cancer (DESKTOP III [NCT #01166737] and GOG 213 [NSC #704865]) comparing secondary cytoreductive surgery followed by platinum-based chemotherapy versus chemotherapy alone have been conducted. The results of the DESKTOP III were recently presented at the American Society of Clinical Oncology meeting in Chicago. It showed a benefit of secondary cytoreductive surgery exclusively in patients with complete resection with a progression-free survival of 5.6 months (P < 0.001). This overview aims to support this task and concentrates on the currently available data regarding surgery in recurrent ovarian cancer. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

The current role of secondary cytoreductive surgery for recurrent ovarian cancer

Eelco de Bree, Dimosthenis Michelakis, Elisavet Anagnostopoulou

Summary: Ovarian cancer is the second most common and fatal gynecological malignancy worldwide, with most patients presenting in advanced stages. Cytoreductive surgery in combination with platinum-based chemotherapy is the standard treatment. Despite advancements, recurrence and death from the disease are still common. The role of secondary cytoreductive surgery in recurrent ovarian cancer is controversial and should be continuously reviewed.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Joo-Hyuk Son, Jimin Lee, Sun-Hyung Yum, Jeeyeon Kim, Tae-Wook Kong, Suk-Joon Chang, Hee-Sug Ryu

Summary: This study evaluated the clinical characteristics of 262 patients with recurrent ovarian cancer to identify factors associated with the selection of patients who would benefit from secondary cytoreductive surgery (SCS). The study found that patients who received SCS had significantly longer median survival compared to those who received chemotherapy alone. Limited regional recurrence emerged as a simplified factor for predicting no residual disease after SCS.

CANCERS (2022)

Add to Collection

Review Oncology

The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis

Claudia Marchetti, Anna Fagotti, Vincenzo Tombolini Fp, Giovanni Scambia Fp, Francesca De Felice

Summary: This study compared secondary cytoreductive surgery followed by systemic therapy with systemic therapy alone for recurrent ovarian cancer patients. The results showed that secondary cytoreductive surgery was associated with significantly better progression-free survival (PFS) improvement, especially for the complete resection subpopulation. Overall survival (OS) was similar between the groups, but favored the complete resection subpopulation.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea

Se Ik Kim, Ji Hyun Kim, Joseph J. Noh, Seung-Ho Kim, Tae Eun Kim, Kidong Kim, Jeong-Yeol Park, Myong Cheol Lim, Jeong-Won Lee, Jae-Weon Kim

Summary: This study investigated the impact of bevacizumab (BEV) use during second-line chemotherapy and secondary cytoreductive surgery (CRS) on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma (OCCC) patients. The results showed that the BEV group had improved progression-free survival (PFS) and overall survival (OS) compared to the non-BEV group. Additionally, the secondary CRS group had significantly better PFS and OS compared to the no surgery group.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis

Min-Hyun Baek, Eun Young Park, Hyeong In Ha, Sang-Yoon Park, Myong Cheol Lim, Christina Fotopoulou, Robert E. Bristow

Summary: This study focused on evaluating the survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. The findings indicated that complete cytoreductions were associated with better survival outcomes and that maximal tumor resection significantly increased overall survival in this patient population.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer

Caixia Jiang, Zhengyu Li

Summary: Research indicates that secondary cytoreductive surgery (SCS) combined with chemotherapy for patients with platinum-sensitive recurrent ovarian cancer can provide significant benefits, especially for those achieving complete gross resection (CGR) which greatly improves survival rates. Various models such as the MSK criteria, the AGO score, and the Tian model have been proposed to predict CGR rate in SCS of ROC patients over the past 15 years.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery

Nicolo Bizzarri, Claudia Marchetti, Carmine Conte, Matteo Loverro, Maria Teresa Giudice, Lorena Quagliozzi, Mariagrazia Distefano, Vito Chiantera, Giovanni Scambia, Anna Fagotti

Summary: The present study aimed to evaluate the oncological outcomes of platinum-sensitive recurrent ovarian cancer patients undergoing secondary cytoreduction (SCS) after treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) at diagnosis, and to compare the performance of different selection models in these patients. It was found that patients treated with NACT/IDS had similar post-recurrence survival outcomes compared to those treated with primary debulking surgery (PDS), and the current selection models could be safely applied to IDS patients.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Correction Medicine, General & Internal

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer (vol 385, pg 2123, 2021)

Philipp Harter, Jalid Sehouli, Ignace Vergote, Gwenael Ferron, Alexander Reuss, Werner Meier, Stefano Greggi, Berit J. Mosgard, Frederic Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, Elisabeth Avall-Lundqvist, Jae-Weon Kim, Jordi Ponce, Francesco Raspagliesi, Gunnar Kristensen, Jean-Marc Classe, Peter Hillemanns, Pernille Jensen, Annette Hasenburg, Sadaf Ghaem-Maghami, Mansoor R. Mirza, Bente Lund, Alexander Reinthaller, Ana Santaballa, Adeola Olaitan, Felix Hilpert, Andreas du Bois

Summary: In patients with recurrent ovarian cancer, cytoreductive surgery followed by chemotherapy resulted in longer overall survival than chemotherapy alone. Patients with a complete resection had the most favorable outcome.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Oncology

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer

Camilla Certelli, Silvio Andrea Russo, Luca Palmieri, Aniello Foresta, Luigi Pedone Anchora, Virginia Vargiu, Francesco Santullo, Anna Fagotti, Giovanni Scambia, Valerio Gallotta

Summary: This review focuses on the role of secondary cytoreductive surgery and specifically minimally-invasive procedures in the treatment of recurrent ovarian cancer, analyzing patient selection, outcomes, criticisms, and future perspectives.

CANCERS (2023)

Add to Collection

Article Oncology

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer

Aditi Bhatt, Snita Sinukumar, Vahan Kepenekian, Praveen Kammar, Sanket Mehta, Sakina Shaikh, Witold Gertych, Naoual Bakrin, Olivier Glehen

Summary: This study aimed to evaluate the incidence of platinum resistant recurrence and early recurrence in patients undergoing interval CRS, as well as the impact of different treatments on recurrence. The results showed that the use of aggressive locoregional therapies like TPP and HIPEC can reduce the incidence of recurrence.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Deep epigastric lymph nodes implication in patients' recurrence pattern after cytoreductive surgery in ovarian peritoneal metastases

Antoine El Asmar, Michael Vouche, Florin Pop, Laura Polastro, Marie Chintinne, Isabelle Veys, Vincent Donckier, Gabriel Liberale

Summary: This study reveals the potential role of the DELN basin and its importance in the recurrence of PMOC. It provides new insights into previously overlooked lymphatic pathways.

EJSO (2023)

Add to Collection

Review Oncology

Minimally invasive interval cytoreductive surgery for advanced ovarian cancer

Alexander Melamed, Eric L. Eisenhauer

Summary: With the increasing use of neoadjuvant chemotherapy, it is apparent that some patients may benefit from less extensive interval cytoreductive surgery performed using minimally invasive techniques. Surgeons in various countries, including the United States, have started adopting these techniques based on their expertise in minimally invasive surgery for other indications in gynecologic oncology. Further research will determine the most suitable patients for this approach.

JOURNAL OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma

Rafael Leite Nunes, Flavio Rodrigues Teixeira, Thiago Pereira Diniz, Carlos Chaves Faloppa, Henrique Mantoan, Alexandre Andre Balieiro Anastacio da Costa, Glauco Baiocchi

Summary: This study evaluated the value of PET/CT in predicting NRD after SCS compared with MSK criteria, iMODEL, and AGO score. Variables correlated with NRD included peritoneal carcinomatosis index, ECOG score, and <= 2 lesions by PET/CT. PET/CT had a sensitivity of 85.7%, positive predictive value of 92.3%, negative predictive value of 33.3%, and accuracy of 81.2% for predicting NRD. The addition of PET/CT did not increase the accuracy of the MSK criteria, iMODEL, or AGO score models.

JOURNAL OF GYNECOLOGIC ONCOLOGY (2023)

Add to Collection

Review Reproductive Biology

The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis

Ting Ding, Dan Tang, Mingrong Xi

Summary: This study found that in recurrent ovarian cancer, secondary cytoreductive surgery plus chemotherapy (SCS + CT) significantly improved patients' PFS and OS compared to chemotherapy alone. Complete resection is crucial for better prognosis, leading to longer PFS and OS compared to incomplete resection, and maximizing survival benefits. Additionally, the incidence of complications within 30 days after surgery was around 21%, with no significant difference compared to the chemotherapy-only group.

JOURNAL OF OVARIAN RESEARCH (2021)

Add to Collection

Article Oncology

Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer

Myeong-Seon Kim, Seung Hun Baek, Joseph J. Noh, Jung In Shim, Jun Hyeok Kang, Soo Young Jeong, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Yoo-Young Lee

Summary: This study investigated the incidence of reactive thrombocytosis and its impact on survival in patients with advanced epithelial ovarian cancer (EOC) after maximal cytoreductive surgery. The results showed that thrombocytosis was observed in 34.8% of patients one week after surgery, and it had the most significant effects on overall survival when observed during adjuvant chemotherapy.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study

Jue-Sheng Ong, Liang-Dar Hwang, Gabriel Cuellar-Partida, Nicholas G. Martin, Georgia Chenevix-Trench, Michael C. J. Quinn, Marilyn C. Cornelis, Puya Gharahkhani, Penelope M. Webb, Stuart MacGregor

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2018)

Add to Collection

Article Oncology

Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy

Florian Heitz, Philipp Harter, Beyhan Ataseven, Sebastian Heikaus, Stephanie Schneider, Sonia Prader, Mareike Bommert, Anette Fisseler-Eckhoff, Alexander Traut, Andreas du Bois

ANNALS OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

French national survey on infective endocarditis and the Melody™ valve in percutaneous pulmonary valve implantation

Sophie Malekzadeh-Milani, Ali Houeijeh, Zakaria Jalal, Sebastien Hascoet, Mohamed Bakloul, Philippe Aldebert, Jean-Francois Piechaud, Francois Heitz, Helene Bouvaist, Claire Dauphin, Patrice Guerin, Olivier Villemain, Jerome Petit, Francois Godart, Jean-Benoit Thambo, Younes Boudjemline

ARCHIVES OF CARDIOVASCULAR DISEASES (2018)

Add to Collection

Article Biochemistry & Molecular Biology

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

Linda E. Kelemen, Madalene Earp, Brooke L. Fridley, Georgia Chenevix-Trench, Peter A. Fasching, Matthias W. Beckmann, Arif B. Ekici, Alexander Hein, Diether Lambrechts, Sandrina Lambrechts, Els Van Nieuwenhuysen, Ignace Vergote, Mary Anne Rossing, Jennifer A. Doherty, Jenny Chang-Claude, Sabine Behrens, Kirsten B. Moysich, Rikki Cannioto, Shashikant Lele, Kunle Odunsi, Marc T. Goodman, Yurii B. Shvetsov, Pamela J. Thompson, Lynne R. Wilkens, Thilo Doerk, Natalia Antonenkova, Natalia Bogdanova, Peter Hillemanns, Ingo B. Runnebaum, Andreas du Bois, Philipp Harter, Florian Heitz, Ira Schwaab, Ralf Butzow, Liisa M. Pelttari, Heli Nevanlinna, Francesmary Modugno, Robert P. Edwards, Joseph L. Kelley, Roberta B. Ness, Beth Y. Karlan, Jenny Lester, Sandra Orsulic, Christine Walsh, Susanne K. Kjaer, Allan Jensen, Julie M. Cunningham, Robert A. Vierkant, Graham G. Giles, Fiona Bruinsma, Melissa C. Southey, Michelle A. T. Hildebrandt, Dong Liang, Karen Lu, Xifeng Wu, Thomas A. Sellers, Douglas A. Levine, Joellen M. Schildkraut, Edwin S. Iversen, Kathryn L. Terry, Daniel W. Cramer, Shelley S. Tworoger, Elizabeth M. Poole, Elisa V. Bandera, Sara H. Olson, Irene Orlow, Liv Cecilie Vestrheim Thomsen, Line Bjorge, Camilla Krakstad, Ingvild L. Tangen, Lambertus A. Kiemeney, Katja K. H. Aben, Leon F. A. G. Massuger, Anne M. van Altena, Tanja Pejovic, Yukie Bean, Melissa Kellar, Linda S. Cook, Nhu D. Le, Angela Brooks-Wilson, Jacek Gronwald, Cezary Cybulski, Anna Jakubowska, Jan Lubinski, Nicolas Wentzensen, Louise A. Brinton, Jolanta Lissowska, Estrid Hogdall, Svend Aage Engelholm, Claus Hogdall, Lene Lundvall, Lotte Nedergaard, Paul D. P. Pharoah, Ed Dicks, Honglin Song, Jonathan P. Tyrer, Iain McNeish, Nadeem Siddiqui, Karen Carty, Rosalind Glasspool, James Paul, Ian G. Campbell, Diana Eccles, Alice S. Whittemore, Valerie McGuire, Joseph H. Rothstein, Weiva Sieh, Steven A. Narod, Catherine M. Phelan, John R. McLaughlin, Harvey A. Risch, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A. Gayther, Aleksandra Gentry-Maharaj, Susan J. Ramus, Anna H. Wu, Celeste Leigh Pearce, Alice W. Lee, Malcolm C. Pike, Jolanta Kupryjanczyk, Agnieszka Podgorska, Joanna Plisiecka-Halasa, Wlodzimierz Sawicki, Ellen L. Goode, Andrew Berchuck

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection

Editorial Material Oncology

ASO Author Reflections: Systematic Lymph Node Dissection in Ovarian Cancer Under Attack

Florian Heitz, Philipp Harter, Andreas du Bois

ANNALS OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

Yaohua Yang, Lang Wu, Xiang Shu, Yingchang Lu, Xiao-Ou Shu, Qiuyin Cai, Alicia Beeghly-Fadiel, Bingshan Li, Fei Ye, Andrew Berchuck, Hoda Anton-Culver, Susana Banerjee, Javier Benitez, Line Bjorge, James D. Brenton, Ralf Butzow, Ian G. Campbell, Jenny Chang-Claude, Kexin Chen, Linda S. Cook, Daniel W. Cramer, Anna defazio, Joe Dennis, Jennifer A. Doherty, Thilo Doerk, Diana M. Eccles, Digna Velez Edwards, Peter A. Fasching, Renee T. Fortner, Simon A. Gayther, Graham G. Giles, Rosalind M. Glasspool, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Holly R. Harris, Florian Heitz, Michelle A. Hildebrandt, Estrid Hogdall, Claus K. Hogdall, David G. Huntsman, Siddhartha P. Kar, Beth Y. Karlan, Linda E. Kelemen, Lambertus A. Kiemeney, Susanne K. Kjaer, Anita Koushik, Diether Lambrechts, Nhu D. Le, Douglas A. Levine, Leon F. Massuger, Keitaro Matsuo, Taymaa May, Iain A. McNeish, Usha Menon, Francesmary Modugno, Alvaro N. Monteiro, Patricia G. Moorman, Kirsten B. Moysich, Roberta B. Ness, Heli Nevanlinna, Hakan Olsson, N. Charlotte Onland-Moret, Sue K. Park, James Paul, Celeste L. Pearce, Tanja Pejovic, Catherine M. Phelan, Malcolm C. Pike, Susan J. Ramus, Elio Riboli, Cristina Rodriguez-Antona, Isabelle Romieu, Dale P. Sandler, Joellen M. Schildkraut, Veronica W. Setiawan, Kang Shan, Nadeem Siddiqui, Weiva Sieh, Meir J. Stampfer, Rebecca Sutphen, Anthony J. Swerdlow, Lukasz M. Szafron, Soo Hwang Teo, Shelley S. Tworoger, Jonathan P. Tyrer, Penelope M. Webb, Nicolas Wentzensen, Emily White, Walter C. Willett, Alicja Wolk, Yin Ling Woo, Anna H. Wu, Li Yan, Drakoulis Yannoukakos, Georgia Chenevix-Trench, Thomas A. Sellers, Paul D. P. Pharoah, Wei Zheng, Jirong Long

CANCER RESEARCH (2019)

Add to Collection

Review Obstetrics & Gynecology

Low-grade Serous Ovarian Carcinoma

Enzo Ricciardi, Thais Baert, Beyhan Ataseven, Florian Heitz, Sonia Prader, Mareike Bommert, Stephanie Schneider, Andreas du Bois, Philipp Harter

GEBURTSHILFE UND FRAUENHEILKUNDE (2018)

Add to Collection

Article Oncology

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

F. Heitz, P. Harter, E. Avail-Lundqvist, A. Reuss, P. Pautier, G. Cormio, N. Colombo, A. Reinthaller, I. Vergote, A. Poveda, P. B. Ottevanger, L. C. Hanker, A. Leminen, J. Alexandre, U. Canzler, J. Sehouli, J. Herrstedt, B. Fiane, M. Merger, A. du Bois

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer

Sonia Prader, Nils Vollmar, Andreas du Bois, Florian Heitz, Stephanie Schneider, Beyhan Ataseven, Mareike Bommert, Kai-Uwe Waltering, Sebastian Heikaus, Jens Albrecht Koch, Pier Francesco Alesina, Alexander Traut, Philipp Harter

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study

Elisabeth Maritschnegg, Florian Heitz, Nina Pecha, Jiri Bouda, Fabian Trillsch, Christoph Grimm, Adriaan Vanderstichele, Christiane Agreiter, Philipp Harter, Eva Obermayr, Ignace Vergote, Robert Zeillinger, Paul Speiser

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)

Add to Collection

Article Multidisciplinary Sciences

Shared heritability and functional enrichment across six solid cancers

Xia Jiang, Hilary K. Finucane, Fredrick R. Schumacher, Stephanie L. Schmit, Jonathan P. Tyrer, Younghun Han, Kyriaki Michailidou, Corina Lesseur, Karoline B. Kuchenbaecker, Joe Dennis, David V. Conti, Graham Casey, Mia M. Gaudet, Jeroen R. Huyghe, Demetrius Albanes, Melinda C. Aldrich, Angeline S. Andrew, Irene L. Andrulis, Hoda Anton-Culver, Antonis C. Antoniou, Natalia N. Antonenkova, Susanne M. Arnold, Kristan J. Aronson, Banu K. Arun, Elisa V. Bandera, Rosa B. Barkardottir, Daniel R. Barnes, Jyotsna Batra, Matthias W. Beckmann, Javier Benitez, Sara Benlloch, Andrew Berchuck, Sonja I. Berndt, Heike Bickeboeller, Stephanie A. Bien, Carl Blomqvist, Stefania Boccia, Natalia V. Bogdanova, Stig E. Bojesen, Manjeet K. Bolla, Hiltrud Brauch, Hermann Brenner, James D. Brenton, Mark N. Brook, Joan Brunet, Hans Brunnstrom, Daniel D. Buchanan, Barbara Burwinkel, Ralf Butzow, Gabriella Cadoni, Trinidad Caldes, Maria A. Caligo, Ian Campbell, Peter T. Campbell, Geraldine Cancel-Tassin, Lisa Cannon-Albright, Daniele Campa, Neil Caporaso, Andre L. Carvalho, Andrew T. Chan, Jenny Chang-Claude, Stephen J. Chanock, Chu Chen, David C. Christiani, Kathleen B. M. Claes, Frank Claessens, Judith Clements, J. Margriet Collee, Marcia Cruz Correa, Fergus J. Couch, Angela Cox, Julie M. Cunningham, Cezary Cybulski, Kamila Czene, Mary B. Daly, Anna defazio, Peter Devilee, Orland Diez, Manuela Gago-Dominguez, Jenny L. Donovan, Thilo Doerk, Eric J. Duell, Alison M. Dunning, Miriam Dwek, Diana M. Eccles, Christopher K. Edlund, Digna R. Velez Edwards, Carolina Ellberg, D. Gareth Evans, Peter A. Fasching, Robert L. Ferris, Triantafillos Liloglou, Jane C. Figueiredo, Olivia Fletcher, Renee T. Fortner, Florentia Fostira, Silvia Franceschi, Eitan Friedman, Steven J. Gallinger, Patricia A. Ganz, Judy Garber, Jose A. Garcia-Saenz, Simon A. Gayther, Graham G. Giles, Andrew K. Godwin, Mark S. Goldberg, David E. Goldgar, Ellen L. Goode, Marc T. Goodman, Gary Goodman, Kjell Grankvist, Mark H. Greene, Henrik Gronberg, Jacek Gronwald, Pascal Guenel, Niclas Hakansson, Per Hall, Ute Hamann, Freddie C. Hamdy, Robert J. Hamilton, Jochen Hampe, Aage Haugen, Florian Heitz, Rolando Herrero, Peter Hillemanns, Michael Hoffmeister, Estrid Hogdall, Yun-Chul Hong, John L. Hopper, Richard Houlston, Peter J. Hulick, David J. Hunter, David G. Huntsman, Gregory Idos, Evgeny N. Imyanitov, Sue Ann Ingles, Claudine Isaacs, Anna Jakubowska, Paul James, Mark A. Jenkins, Mattias Johansson, Mikael Johansson, Esther M. John, Amit D. Joshi, Radka Kaneva, Beth Y. Karlan, Linda E. Kelemen, Tabea Kuhl, Kay-Tee Khaw, Elza Khusnutdinova, Adam S. Kibel, Lambertus A. Kiemeney, Jeri Kim, Susanne K. Kjaer, Julia A. Knight, Manolis Kogevinas, Zsofia Kote-Jarai, Stella Koutros, Vessela N. Kristensen, Jolanta Kupryjanczyk, Martin Lacko, Stephan Lam, Diether Lambrechts, Maria Teresa Landi, Philip Lazarus, Nhu D. Le, Eunjung Lee, Flavio Lejbkowicz, Heinz-Josef Lenz, Goska Leslie, Davor Lessel, Jenny Lester, Douglas A. Levine, Li Li, Christopher I. Li, Annika Lindblom, Noralane M. Lindor, Geoffrey Liu, Fotios Loupakis, Jan Lubinski, Lovise Maehle, Christiane Maier, Arto Mannermaa, Loic Le Marchand, Sara Margolin, Taymaa May, Lesley McGuffog, Alfons Meindl, Pooja Middha, Austin Miller, Roger L. Milne, Robert J. MacInnis, Francesmary Modugno, Marco Montagna, Victor Moreno, Kirsten B. Moysich, Lorelei Mucci, Kenneth Muir, Anna Marie Mulligan, Katherine L. Nathanson, David E. Neal, Andrew R. Ness, Susan L. Neuhausen, Heli Nevanlinna, Polly A. Newcomb, Lisa F. Newcomb, Finn Cilius Nielsen, Liene Nikitina-Zake, Borge G. Nordestgaard, Robert L. Nussbaum, Kenneth Offit, Edith Olah, Ali Amin Al Olama, Olufunmilayo I. Olopade, Andrew F. Olshan, Hakan Olsson, Ana Osorio, Hardev Pandha, Jong Y. Park, Nora Pashayan, Michael T. Parsons, Tanja Pejovic, Kathryn L. Penney, Wilbert H. M. Peters, Catherine M. Phelan, Amanda I. Phipps, Dijana Plaseska-Karanfilska, Miranda Pring, Darya Prokofyeva, Paolo Radice, Kari Stefansson, Susan J. Ramus, Leon Raskin, Gad Rennert, Hedy S. Rennert, Elizabeth J. van Rensburg, Marjorie J. Riggan, Harvey A. Risch, Angela Risch, Monique J. Roobol, Barry S. Rosenstein, Mary Anne Rossing, Kim De Ruyck, Emmanouil Saloustros, Dale P. Sandler, Elinor J. Sawyer, Matthew B. Schabath, Johanna Schleutker, Marjanka K. Schmidt, V. Wendy Setiawan, Hongbing Shen, Erin M. Siegel, Weiva Sieh, Christian F. Singer, Martha L. Slattery, Karina Dalsgaard Sorensen, Melissa C. Southey, Amanda B. Spurdle, Janet L. Stanford, Victoria L. Stevens, Sebastian Stintzing, Jennifer Stone, Karin Sundfeldt, Rebecca Sutphen, Anthony J. Swerdlow, Eloiza H. Tajara, Catherine M. Tangen, Adonina Tardon, Jack A. Taylor, M. Dawn Teare, Manuel R. Teixeira, Mary Beth Terry, Kathryn L. Terry, Stephen N. Thibodeau, Mads Thomassen, Line Bjorge, Marc Tischkowitz, Amanda E. Toland, Diana Torres, Paul A. Townsend, Ruth C. Travis, Nadine Tung, Shelley S. Tworoger, Cornelia M. Ulrich, Nawaid Usmani, Celine M. Vachon, Els Van Nieuwenhuysen, Ana Vega, Miguel Elias Aguado-Barrera, Qin Wang, Penelope M. Webb, Clarice R. Weinberg, Stephanie Weinstein, Mark C. Weissler, Jeffrey N. Weitzel, Catharine M. L. West, Emily White, Alice S. Whittemore, H-Erich Wichmann, Fredrik Wiklund, Robert Winqvist, Alicja Wolk, Penella Woll, Michael Woods, Anna H. Wu, Xifeng Wu, Drakoulis Yannoukakos, Wei Zheng, Shanbeh Zienolddiny, Argyrios Ziogas, Kristin K. Zorn, Jacqueline M. Lane, Richa Saxena, Duncan Thomas, Rayjean J. Hung, Brenda Diergaarde, James Mckay, Ulrike Peters, Li Hsu, Montserrat Garcia-Closas, Rosalind A. Eeles, Georgia Chenevix-Trench, Paul J. Brennan, Christopher A. Haiman, Jacques Simard, Douglas F. Easton, Stephen B. Gruber, Paul D. P. Pharoah, Alkes L. Price, Bogdan Pasaniuc, Christopher I. Amos, Peter Kraft, Sara Lindstrom

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Oncology

Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery

Marlene Kranawetter, Beyhan Ataseven, Christoph Grimm, Stephanie Schneider, Stefan Riss, Pier Alesina, Sonia Prader, Martin K. Walz, Felix Harpain, Anton Stift, Florian Heitz, Alexander Reinthaller, Stephan Polterauer, Philipp Harter, Andreas du Bois

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment Monitoring

Elena Ioana Braicu, Andreas du Bois, Jalid Sehouli, Julia Beck, Sonia Prader, Hagen Kulbe, Bernd Eiben, Philipp Harter, Alexander Traut, Klaus Pietzner, Ralf Glaubitz, Beyhan Ataseven, Radoslav Chekerov, Christoph Keck, Thomas Winkler, Sebastian Heikaus, Peggy Gellendin, Ekkehard Schuetz, Florian Heitz

Summary: This study demonstrates the use of low-coverage cell-free tumor DNA sequencing to detect chromosomal instability (CI) in ovarian cancer patients. The CI can serve as a reliable marker for ovarian cancer detection and is associated with prognostic and predictive clinical measures. The findings suggest that ctDNA analysis based on the CNI-Score can be an important tool for diagnostics and therapy monitoring in high-grade epithelial ovarian cancer.

CANCERS (2022)

Add to Collection

Article Oncology

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer

Florian Heitz, Beyhan Ataseven, Claudia Staniczok, Carsten Denkert, Kerstin Rhiem, Eric Hahnen, Sebastian Heikaus, Malak Moubarak, Julia Welz, Timoleon Dagres, Vasilios Vrentas, Mareike Bommert, Stephanie Schneider, Nicole Concin, Philipp Harter

Summary: Testing for HRD is crucial for recommending appropriate therapy in primary high-grade ovarian cancer patients. While patients with a BRCA mutation are defined as HRD deficient, approximately 20% of patients without BRCA mutation can still have HRD deficiency based on tumor genomic analysis. This study highlights the importance of obtaining sufficient tumor tissue and conducting additional BRCA germline testing to improve the accuracy of HRD testing and inform treatment decisions.

CANCERS (2023)

Add to Collection

Article Oncology

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients

Majdi Imterat, Philipp Harter, Kerstin Rhiem, Florian Heitz, Stephanie Schneider, Nicole Concin, Malak Moubarak, Julia Welz, Vasileios Vrentas, Alexander Traut, Eric Hahnen, Rita Schmutzler, Andreas du Bois, Beyhan Ataseven

Summary: Limited data is available on deleterious variants in genes other than BRCA1/2. A retrospective cohort study investigated the impact of germline mutations on ovarian cancer prognosis. The study found that germline mutations, including BRCA1/2 and other genes, were detected in a quarter of ovarian cancer patients and were associated with significantly better outcomes in terms of overall survival and progression-free survival.

CANCERS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.